Wells Fargo Maintains Equal-Weight on Merck & Co, Lowers Price Target to $110
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Mohit Bansal has maintained an Equal-Weight rating on Merck & Co (NYSE:MRK) but has lowered the price target from $125 to $110.
November 01, 2024 | 6:45 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Wells Fargo has maintained an Equal-Weight rating on Merck & Co but reduced the price target from $125 to $110, indicating a more cautious outlook.
The lowering of the price target from $125 to $110 by Wells Fargo suggests a more cautious outlook on Merck & Co's stock performance. This could lead to a negative short-term impact on the stock price as investors may adjust their expectations based on the new target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100